New Therapeutic Targets in the Treatment of Generalized Myasthenia Gravis: Understanding Disease Pathways and Pharmacist-Led Strategies for Optimized Care

Program Description

Generalized myasthenia gravis (gMG) can result in significant disease burden for patients due to fluctuating, often severe, muscle weakness, debilitating fatigue, and a high potential for respiratory crises. Research into the pathophysiology of gMG has uncovered several immunopathologic mechanisms contributing to the disease, particularly the critical roles of autoantibodies, complement activation, and the neonatal Fc receptor (FcRn). This session will provide specialty pharmacists with a foundational understanding of gMG pathophysiology and the latest approved and emerging agents, including FcRn inhibitors, complement inhibitors, and B-cell–directed therapies, with a review of their mechanism of action, efficacy, and safety profiles. Specialty pharmacists must be familiar with the clinical data and access considerations to ensure timely and appropriate care for patients with gMG. By reviewing these novel treatments and detailing the evolving responsibilities of the specialty pharmacist in care coordination, patient education, adherence monitoring, and adverse effect management, this session will support specialty pharmacists in successfully navigating the treatment landscape of gMG. Patient case discussions will also be incorporated, providing opportunities to apply knowledge of gMG management and treatment selection to complex, real-world patient scenarios.

Target Audience: Specialty Pharmacist

Type of Activity: Application

Release date: November 21, 2025

Expiration date: November 21, 2026

Learner level: Foundational, Intermediate

Time to complete activity: 1.5 hour

Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Explain the immunopathologic mechanisms contributing to generalized myasthenia gravis (gMG), including the role of autoantibodies, complement, and the neonatal Fc receptor (FcRn)
• Analyze emerging and approved therapies for gMG, including FcRn inhibitors, complement inhibitors, and B-cell directed therapies, in the context of mechanism of action, efficacy, and safety
• Identify the evolving role of specialty pharmacists in managing gMG, including coordination of care, patient education, treatment adherence, and adverse effect management